![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This merger supports Ocuphire for advancement of its late-clinical stage small molecule ophthalmic pipeline including its Nyxol® Eye Drops, a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Ocuphire Pharma
Deal Size: $21.1 million Upfront Cash: Undisclosed
Deal Type: Merger June 18, 2020
Details:
The company had previously disclosed that it was evaluating the development strategy for RX-5902, including whether to proceed with the trial.
Lead Product(s): RX-5902
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 09, 2020